

B2  
CONT'D

37. (Amended) The [porcine cell] composition of claim 36, wherein the antigen is LFA-3.

38. (Amended) The [porcine cell] composition of claim 36, wherein the antigen is ICAM-1.

39. (Amended) The [porcine cell] composition of claim 36, wherein the antigen is an MHC class I antigen or an MHC class II antigen.

40. (Amended) The [porcine cell] composition of claim 36, wherein the antigen is masked with at least one masking agent.

Sub. E2

41. (Amended) The [porcine cell] composition of claim 40, wherein the antigen is masked with at least two masking agents.

42. (Amended) The [porcine cell] composition of claim 41, wherein the at least two masking agents are obtained from polyclonal antisera raised against the antigen.

43. (Amended) The [porcine cell] composition of claim 36, wherein the cell or tissue has at least two different antigens which are masked with at least two different masking agents.

44. (Amended) The [porcine cell] composition of claim 36, wherein expression of the antigen on the cell is inhibited.

B<sup>2</sup>  
CONT'D.

45. (Amended) The [porcine cell] composition of claim 36, wherein the cell or tissue is harvested from a transgenic animal which has a diminished capacity to express the antigen on the surface of the cell.

46. (Amended) The [porcine cell] composition of claim 36, wherein the cell or tissue comprises a genetically engineered cell with increased capacity to express a cellular component.

47. (Amended) The [porcine cell] composition of claim 40, wherein the antigen is an MHC class I antigen or an MHC class II antigen.

48. (Amended) The [porcine cell] composition of claim 44, wherein the masking agent is a non-lytic anti-MHC class I antibody or fragment thereof or an anti-MHC class II antibody or fragment thereof.

49. (Amended) The [porcine cell] composition of claim 48, wherein the anti-MHC class I antibody fragment is an anti-MHC class I F(ab')<sub>2</sub> fragment.

50. (Amended) The [porcine cell] composition of claim 36, which comprises [is] a pancreatic islet cell.

51. (Amended) The [porcine cell] composition of claim 36, which comprises [is] a kidney cell.

52. (Amended) The [porcine cell] composition of claim 36, which comprises [is] a heart cell.

53. (Amended) The [porcine cell] composition of claim 36, which comprises [is] a muscle cell.

54. (Amended) The [porcine cell] composition of claim 36, which comprises [is] a liver cell.

55. (Amended) The [porcine cell] composition of claim 36, which comprises [is] a lung cell.

56. (Amended) The [porcine cell] composition of claim 36, which comprises [is] an endothelial cell.

57. (Amended) The [porcine cell] composition of claim 36, which comprises [is] a neuronal cell.

58. (Amended) The [porcine cell] composition of claim 36, which comprises [is] a parenchymal cell from a tissue or organ.

59. (Amended) A transplantable composition for use in humans comprising a cell or tissue of a type normally [non-lymphocytic porcine cell] bearing a surface antigen capable of causing an immune response against the cell in a human recipient, wherein the

B2  
CONTD.

Sub E3

Sub  
D2

Sub E3  
B2  
CONTR

antigen is masked such that upon introduction of the composition into a human, lysis of said cell is prevented [to inhibit antigen-mediated rejection of the cell in the recipient].

60. (Amended) A transplantable composition for use in humans comprising a [porcine] cell or tissue and at least one masking agent, wherein the masking agent binds to a surface antigen of the [porcine] cell which is capable of causing an immune response against the cell in a human recipient such that upon introduction of the composition into a human, lysis of said cell is prevented.

61. (Amended) A method for inhibiting rejection by a human recipient of a porcine [cells] cell or tissue having a surface antigen which is capable of causing an immune response against the [cells] cell or tissue in the recipient, said method comprising modifying, masking, or partially or wholly eliminating the antigen to inhibit antigen-mediated rejection of the cells in the recipient, such that upon introduction of the cell or tissue into a human, lysis of said cell or tissue is prevented.

62. The method of claim 61, wherein the antigen is LFA-3

63. The method of claim 61, wherein the antigen is ICAM-1.

64. The method of claim 61, wherein the antigen is an MHC class I antigen or an MHC class II antigen.

65. (Amended) The method of claim 61, wherein expression of the antigen on the

[cells] cell or tissue is inhibited.

B2  
Cont'd.

66. (Amended) The method of claim 61, wherein the [cells] cell or tissue is [are] harvested from a transgenic animal which has diminished capacity to express the antigen on the surface of the cells.

67. (Amended) The method of claim 61, wherein the [cells comprise] cell or tissue is genetically engineered [cells] with increased capacity to express a cellular component.

68. The method of claim 61, wherein the antigen is masked with at least one masking agent.

69. (Amended) The method of claim 68, wherein the antigen is masked with at least two masking agents [agent].

70. (Amended) The method of claim 61, wherein the [cells have] cell or tissue has at least two different antigens which are masked with at least two different masking agents.

71. The method of claim 70, wherein the at least two masking agents are obtained from polyclonal antisera raised against the antigen.

72. The method of claim 68, wherein the antigen is an MHC class I antigen or an MHC class II antigen.

73. The method of claim 72, wherein the masking agent is an anti-MHC class I antibody or fragment thereof or an anti-MHC class II antibody or fragment thereof.

74. The method of claim 73, wherein the anti-MHC class I antibody fragment is an anti-MHC class I F(ab')<sub>2</sub> fragment.

75. (Amended) The method of claim 61, wherein the [cells are] cell or tissue comprises a pancreatic islet [cells] cell.

76. (Amended) The method of claim 61, wherein the [cells are] cell or tissue comprises a kidney [cells] cell.

77. (Amended) The method of claim 61, wherein the [cells are] cell or tissue comprises a heart [cells] cell.

78. (Amended) The method of claim 61, wherein the [cells are] cell or tissue comprises a muscle [cells] cell.

79. (Amended) The method of claim 61, wherein the [cells are] cell or tissue comprises a liver [cells] cell.

80. (Amended) The method of claim 61, wherein the [cells are] cell or tissue comprises a lung [cells] cell.

B2  
comb

81. (Amended) The method of claim 61, wherein the [cells are] cell or tissue comprises an endothelial [cells] cell.

B3  
Conc'n

82. (Amended) The method of claim 61, wherein the [cells are] cell or tissue comprises a neuronal [cells] cell.

83. (Amended) The method of claim 61, wherein the [cells are] cell or tissue comprises a parenchymal [cells] cell from a tissue or organ.

---

Add the following new claims.

---

84. A method for preparing a cell or tissue for transplantation in a human, said method comprising modifying, eliminating, or masking of an antigen of said cell or tissue which is capable of causing an immune response in the recipient, such that upon introduction of the cell or tissue into a recipient animal, lysis of said cell or tissue is prevented.

B3  
Conc'n

85. The method of claim 84, wherein the antigen is selected from the group consisting of: LFA-3, ICAM-1, and an MHC class I antigen or an MHC class II antigen.

86. The method of claim 84, wherein the antigen is masked with at least one masking agent.

87. The method of claim 86, wherein the masking agent is an anti-MHC class I antibody or fragment thereof or an anti-MHC class II antibody or fragment thereof.